FLASCO

Boehringer Ingelheim – Biomarker Testing

  • FLASCO
  • September 4, 2015

Boehringer Ingelheim has a website that provides information to assist with biomarker testing on Advanced Non Small Cell Lung Cancer.  Explore “Let’s Test” for a wealth of resources.  In the age of personalized medicine, oncologists can routinely order biomarker tests for their patients with advanced NSCLC—and use the results to consider more tailored treatment. Treatment decisions are increasingly informed by appropriate diagnostic technique.  Access more information designed for oncologists!  Testing for molecular biomarkers, such as EGFR mutation and ALK rearrangement, represents the cutting edge of pathology in advanced NSCLC.  Access more information designed for pathologists! Collection of sufficient tissue by pulmonologists, interventional radiologists, thoracic surgeons, and other physicians who perform biopsies is a critical step in the biomarker testing process in NSCLC.  Access more information designed for physicians who perform biopsies!  Patients look to allied healthcare professionals (oncology nurse practitioners, physician assistants, and nurses) to learn more about how biomarkers, such as EGFR mutations and ALK rearrangements, inform the cancer treatment plan.  Access more information designed for allied HCPs!  Visit www.letstestnow.com to Access Information today!

Who’s Online

There are no users currently online